Nanjing King-Friend Biochemical Pharmaceutical Co (SHSE:603707) 3-Year EBITDA Growth Rate : 0.00% (As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Nanjing King-Friend Biochemical Pharmaceutical Co 3-Year EBITDA Growth Rate?

Nanjing King-Friend Biochemical Pharmaceutical Co's EBITDA per Share for the three months ended in Mar. 2024 was ¥0.14.

During the past 12 months, Nanjing King-Friend Biochemical Pharmaceutical Co's average EBITDA Per Share Growth Rate was -142.80% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

During the past 11 years, the highest 3-Year average EBITDA Per Share Growth Rate of Nanjing King-Friend Biochemical Pharmaceutical Co was 66.80% per year. The lowest was 11.20% per year. And the median was 47.40% per year.

Competitive Comparison of Nanjing King-Friend Biochemical Pharmaceutical Co's 3-Year EBITDA Growth Rate

For the Drug Manufacturers - Specialty & Generic subindustry, Nanjing King-Friend Biochemical Pharmaceutical Co's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Nanjing King-Friend Biochemical Pharmaceutical Co's 3-Year EBITDA Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Nanjing King-Friend Biochemical Pharmaceutical Co's 3-Year EBITDA Growth Rate distribution charts can be found below:

* The bar in red indicates where Nanjing King-Friend Biochemical Pharmaceutical Co's 3-Year EBITDA Growth Rate falls into.

Nanjing King-Friend Biochemical Pharmaceutical Co 3-Year EBITDA Growth Rate Calculation

This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.

Nanjing King-Friend Biochemical Pharmaceutical Co (SHSE:603707) 3-Year EBITDA Growth Rate Explanation

EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.

Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Nanjing King-Friend Biochemical Pharmaceutical Co 3-Year EBITDA Growth Rate Related Terms

Thank you for viewing the detailed overview of Nanjing King-Friend Biochemical Pharmaceutical Co's 3-Year EBITDA Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Nanjing King-Friend Biochemical Pharmaceutical Co (SHSE:603707) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nanjing King-Friend Biochemical Pharmaceutical Co Ltd (SHSE:603707) » Definitions » 3-Year EBITDA Growth Rate

Traded in Other Exchanges

N/A

Address

1/16 Xuefu Road, Nanjing High-Tech Zone, Nanjing, CHN, 210061

Website

http://www.nkf-pharma.com

Nanjing King-Friend Biochemical Pharmaceutical Co Ltd is a China-based company engaged in the research and development, import and export of medicines and health products. The main products of the company are Heparin sodium and low molecular weight heparin. Geographically, the business activities are carried out through China and it exports the product mainly to the European and American countries.

Executives

Huang Xi Wei	Director
Liu Zu Qing	Supervisors
Xie Ju Hua	Director
Wu Gui Ping	senior management
Tang Yong Qun	Director
Qian Xiao Jie	senior management

Nanjing King-Friend Biochemical Pharmaceutical Co (SHSE:603707) Headlines

No Headlines